|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:voriconazole
|
|
gptkbp:approvalYear
|
2002
|
|
gptkbp:ATCCode
|
gptkb:J02AC03
|
|
gptkbp:CASNumber
|
gptkb:137234-62-9
|
|
gptkbp:chemicalFormula
|
gptkb:C16H14F3N5O
|
|
gptkbp:contraindication
|
hypersensitivity to voriconazole
|
|
gptkbp:drugClass
|
triazole antifungal
|
|
gptkbp:eliminationHalfLife
|
6 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Vfend
|
|
gptkbp:indication
|
immunocompromised patients with fungal infections
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Pfizer
|
|
gptkbp:metabolism
|
liver (CYP2C19, CYP2C9, CYP3A4)
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
rash
hallucinations
visual disturbances
liver enzyme elevation
|
|
gptkbp:usedFor
|
gptkb:esophageal_candidiasis
gptkb:invasive_aspergillosis
candidemia
treatment of fungal infections
serious fungal infections caused by Fusarium
serious fungal infections caused by Scedosporium
|
|
gptkbp:bfsParent
|
gptkb:voriconazole
|
|
gptkbp:bfsLayer
|
7
|